- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Theravance Inc. (THRX)
by latest | most commented
-
15 Overvalued Small Caps from Russell 2000
-
2009 Looking Good for Theravance
-
FDA Calendar: 18 Hot Summer Trades
-
Klarman's Baupost Group Bets Big on Capitalsource, News Corp.
-
FDA, Clinical Trial Updates: Pro-Pharma Looks Promising
-
Theravance Narrows Its Losses
-
20 'Bathwater Babies' and 15 'Dogs with Fleas' for the Week
-
FDA, Clinical Trial Calendar Updates: Theravance, Gilead, Teva, Alnylam, ReNeuron
-
Tudor Investment Takes New Positions in Financials, Among Others
-
Hedge Fund Portfolio Tracking: Seth Klarman's Baupost Group, Q4 2008
-
Updated Clinical Trial Notes on Somaxon, Theravance
-
Seth Klarman's Best Ideas (for Now)
-
Eye-Catching Portfolio Moves by Klarman, Witmer and Einhorn
-
Updated Clinical Trial and FDA Calendars
-
Baupost Group (Seth Klarman): Portfolio Update
-
Hedge Fund Tracking: Seth Klarman & Baupost Group, Q3 2008
-
Three-Month, Updated FDA Decision Calendar
-
73 Decision Dates on Updated FDA Calendar
-
15 Value Hedge Funds - Portfolio Update
-
Baupost Group - Portfolio Holdings
-
Ten Companies Involved in Treating Asthma
-
Tuesday's Options Report: XLF, AIG, ALB, THRX, SGP, CPHD, IGT, PDE
-
The Long Case for Targanta Therapeutics
-
FDA Sets Date for Theravance Drug Review
-
Top 10 Emerging Biotech Stocks
-
Biotech Day In Review: Cell Genesys Climbs On GVAX Results
-
Biotech Day In Review: Genentech Loses Cabilly Patent Ruling
-
Biotech Stocks Day-in-Review: Amgen Strikes Drug Deal With Cytokinetics